Zealand Pharma A/S Q2 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst : A couple of questions for me here as well. So just on HypoPal. So I'm just wondering if there's any -- well, in regards to the prelaunch preparations for this, I'm just wondering if you've started to sort of engage with payers. And if that's the case, do you have any feedback so far? And also, I guess you're up for sort of a mid-cycle review here next month. So I'm just wondering if is it fair to assume that you -- we should not expect any outcome on this one? And then just turning to the amylin analog. So I understand that you can co-formulate with move to GLP-1s. So I'm just wondering if this potentially could become part of the clinical pipeline in the near-term or maybe looking for a different profile for this candidate? And then maybe just lastly, just on glepaglutide, the recruitment here. I'm just wondering, how does the U.S. look -- I'm just wondering if you are still in for at least a 30% U.S. patients in that [audience], and if not, any indication that it could become a problem for the FDA.